
Novo Nordisk has revealed its intention to restructure its research & development operations “to accelerate the expansion and diversification of …

Sanofi’s Dupixent (dupilumab) has made a strong showing as a monotherapy at Phase 3 in the treatment of moderate-to-severe atopic …

NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …

UCB has joined in on the wave of new psoriasis data emerging from the European Academy of Dermatology and Venereology …

As Hurricane Florence begins to breach the Southeast Coast, major pharma firms have announced they are enacting contingency plans, including …

Gene and cell therapy group Oxford Biomedica has announced plans to expand its business with a new site located not …

Novartis was yet another company to reveal new data on a psoriasis drug at the European Academy of Dermatology and …

Celgene made its voice heard amongst the chorus of new psoriasis data emerging from the European Academy of Dermatology and …

Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …

Bavencio (avelumab), Merck KGaA and Pfizer’s human anti-programmed death ligand-1 (PD-L1) antibody, combined with the latter’s Inlyta (axitinib) has shown …

Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …

Public Health England has revealed that an enhanced, “adjuvanted” vaccine is to be made available for over-65s this winter, and …

British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …

A new report from Public Health England (PHE) has illuminated the primary health concerns in UK society today, revealing the …

Alcon, the eyecare unit of Novartis, is set to move to a new home next year, after its parent company …